You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Good morning health tech readers!

Read the rest…

SAN MATEO, Calif. — Peyton Greenside, CEO of BigHat Biosciences, has hot takes. 

Her company designs antibody therapies using machine-learning, but she doesn’t like demos in which people open their computers and show off how fast they can design a drug. “If you want me to design you a protein right now in six hours, I’m happy to do it,” she said.

In fact, she can do it in 20 minutes. But if you’re actually in the business of making drugs, you are still going to have to do all the downstream tests, which take time and lots of money, Greenside said. “That’s where the hard work is, is making the actual drug.” 

Continue to STAT+ to read the full story…